Save your place

Sign in to WhoBought

Please try again later.

4D Molecular Therapeutics, Inc. (FDMT) institutional ownership

Latest close $11.09 Jul 20, 2026
Market cap$297M 52-week range SectorHealthcare
Funds holding · Q1 2026
137
reported FDMT position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
61 buyers · 76 sellers

4D Molecular Therapeutics, Inc. (FDMT) price and institutional activity

Dates

Q1 2026

$0 bought by 61 investors
Trails Edge Capital Partners, LPJanus Henderson Group PLC +59 more
$0 sold by 76 investors
Bvf IncPoint72 Asset Management, L.P. +74 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

4D Molecular Therapeutics, Inc. (FDMT) institutional activity · 137

Investor Type Est. change Change Δ Own Date
Bvf Inc · Reduced
Change −1.8M Date Q1 2026
Bvf Inc Reduced· Q1 2026 −1.8M Q1 2026
Point72 Asset Management, L.P. · Exited
Change −1.5M Δ Own −100.0% Date Q1 2026
Point72 Asset Management, L.P. Exited· Q1 2026 −1.5M −100.0% Q1 2026
Trails Edge Capital Partners, LP · New
Change +1.3M Date Q1 2026
Trails Edge Capital Partners, LP New· Q1 2026 +1.3M Q1 2026
Janus Henderson Group PLC · Added
Change +611K Date Q1 2026
Janus Henderson Group PLC Added· Q1 2026 +611K Q1 2026
Ra Capital Management, L.P. · Reduced
Change −603K Date Q1 2026
Ra Capital Management, L.P. Reduced· Q1 2026 −603K Q1 2026
Baker Bros. Advisors LP · Exited
Change −476K Δ Own −100.0% Date Q1 2026
Baker Bros. Advisors LP Exited· Q1 2026 −476K −100.0% Q1 2026
Nuveen, LLC · Added
Change +403K Date Q1 2026
Nuveen, LLC Added· Q1 2026 +403K Q1 2026
Propel Bio Management, LLC · New
Change +380K Date Q1 2026
Propel Bio Management, LLC New· Q1 2026 +380K Q1 2026
Adage Capital Partners Gp, L.L.C. · Added
Change +370K Date Q1 2026
Adage Capital Partners Gp, L.L.C. Added· Q1 2026 +370K Q1 2026
Morgan Stanley · Reduced
Change −327K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −327K Q1 2026
Arrowmark Colorado Holdings LLC · Reduced
Change −283K Date Q1 2026
Arrowmark Colorado Holdings LLC Reduced· Q1 2026 −283K Q1 2026
Two Sigma Advisers, LP · Exited
Change −275K Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −275K −100.0% Q1 2026
Citadel Advisors LLC Added· Q1 2026 +244K +1227.8% Q1 2026
Dimensional · Added
Change +228K Date Q1 2026
Dimensional Added· Q1 2026 +228K Q1 2026
Two Sigma Investments, LP · Reduced
Change −213K Δ Own −63.2% Date Q1 2026
Two Sigma Investments, LP Reduced· Q1 2026 −213K −63.2% Q1 2026
Data through Q1 2026 · filed Jun 3, 2026
15 of 137

Famous investor activity in 4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Kirn David · Director 2 operations −$189K
Price $12.01–$12.84 Qty −16K Owned 884K ΔOwn −1.7% Trade date Jul 10, 2026 Filed date Jul 14, 2026
Kirn David Director 2 operations $12.01–$12.84 −16K −$189K 884K −1.7% Jul 10, 2026 Jul 14, 2026
Kirn David · Director Sell −$548K
Price $12.87 Qty −43K Owned 900K ΔOwn −4.5% Trade date Jul 9, 2026 Filed date Jul 14, 2026
Kirn David Director Sell $12.87 −43K −$548K 900K −4.5% Jul 9, 2026 Jul 14, 2026
Bizily Scott · Officer Sell −$92K
Price $14.00 Qty −7K Owned 9K ΔOwn −43.2% Trade date Jun 30, 2026 Filed date Jul 2, 2026
Bizily Scott Officer Sell $14.00 −7K −$92K 9K −43.2% Jun 30, 2026 Jul 2, 2026
Bizily Scott · Officer 4 operations 0
Price $4.14–$6.49 Owned 4K Trade date Jun 30, 2026 Filed date Jul 2, 2026
Bizily Scott Officer 4 operations $4.14–$6.49 0 4K Jun 30, 2026 Jul 2, 2026
Bizily Scott · Officer Sell −$118K
Price $12.00 Qty −10K Owned 9K ΔOwn −53.2% Trade date Jun 23, 2026 Filed date Jun 25, 2026
Bizily Scott Officer Sell $12.00 −10K −$118K 9K −53.2% Jun 23, 2026 Jun 25, 2026
Bizily Scott · Officer 2 operations 0
Price $4.14 Owned 64K Trade date Jun 23, 2026 Filed date Jun 25, 2026
Bizily Scott Officer 2 operations $4.14 0 64K Jun 23, 2026 Jun 25, 2026
Kirn David · Director Sell −$1.2M
Price $10.47 Qty −115K Owned 942K ΔOwn −10.9% Trade date Jun 22, 2026 Filed date Jun 23, 2026
Kirn David Director Sell $10.47 −115K −$1.2M 942K −10.9% Jun 22, 2026 Jun 23, 2026
Tomasello Shawn · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Tomasello Shawn Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Theuer Charles · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Theuer Charles Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Miller-Rich Nancy · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Miller-Rich Nancy Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Gray Susannah · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Gray Susannah Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Milligan John F. · Director Grant (A) 75K
Owned 75K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Milligan John F. Director Grant (A) 75K 75K Jun 17, 2026 Jun 18, 2026
Sblendorio Glenn · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Sblendorio Glenn Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Chacko Jacob · Director Grant (A) 50K
Owned 50K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Chacko Jacob Director Grant (A) 50K 50K Jun 17, 2026 Jun 18, 2026
Kirn David · Director Sell −$19K
Price $10.02 Qty −2K Owned 1.1M Trade date Jun 1, 2026 Filed date Jun 2, 2026
Kirn David Director Sell $10.02 −2K −$19K 1.1M Jun 1, 2026 Jun 2, 2026
15 of 35
15 of 35 Sign in to continue to older insider transactions.

4D Molecular Therapeutics, Inc. (FDMT) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Blackrock, Inc. 5.0M
% of shares outstanding 10.7% Filing date Dec 6, 2024
Blackrock, Inc. 5.0M 10.7% Dec 6, 2024
Ra Capital Management, L.P. 5.1M
% of shares outstanding 9.9% Filing date May 15, 2026
Ra Capital Management, L.P. 5.1M 9.9% May 15, 2026
Venrock Healthcare Capital Partners Iii, L.P. 4.4M
% of shares outstanding 8.9% Filing date Feb 14, 2024
Venrock Healthcare Capital Partners Iii, L.P. 4.4M 8.9% Feb 14, 2024
BlackRock Inc. 3.5M
% of shares outstanding 8.1% Filing date Jan 25, 2024
BlackRock Inc. 3.5M 8.1% Jan 25, 2024
Deep Track Capital, LP
% of shares outstanding 7.9% Filing date Nov 14, 2024
Deep Track Capital, LP 7.9% Nov 14, 2024
Biotechnology Value Fund L P 3.9M
% of shares outstanding 7.3% Filing date May 15, 2026
Biotechnology Value Fund L P 3.9M 7.3% May 15, 2026
Goldman Sachs Group Inc 3.6M
% of shares outstanding 6.9% Filing date Nov 6, 2024
Goldman Sachs Group Inc 3.6M 6.9% Nov 6, 2024
Janus Henderson Group PLC 3.1M
% of shares outstanding 6.0% Filing date Nov 14, 2024
Janus Henderson Group PLC 3.1M 6.0% Nov 14, 2024
8 of 12

4D Molecular Therapeutics, Inc. (FDMT) ownership FAQ

Who owns FDMT?

137 reporting institutions disclosed FDMT position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.